Compare Ginkgo Bioworks Holdings Inc (DNA) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Raymond James Financial, Inc. — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while Raymond James Financial, Inc. trades at $179.97 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 68.5× Ginkgo Bioworks Holdings Inc's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | RJF | |
|---|---|---|
Market Cap | $505.73M | $34.63B |
Sector | Health | Financials |
52-Week High | $16.14 | $180.55 |
52-Week Low | $5.48 | $140.89 |
Enterprise Value | $607.68M | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.
DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.
Raymond James Financial (RJF) trades at $181.18, up 1.17% with strong technical momentum including a golden cross formation. The company reported record Q3 2026 earnings of $3.14 per share, beating estimates by 7.2%, driven by 16% revenue growth to $3.93 billion. Analyst consensus remains positive with 44% buy ratings and a $183.75 price target, slightly above current levels. The stock shows bullish moving average signals while RSI indicates potential overbought conditions near-term.
RJF demonstrates solid fundamental growth with consistent earnings beats and expanding profit margins, though valuation appears fair at current levels. Key risks include market sensitivity to capital markets performance and competitive advisor recruitment landscape. The technical setup suggests near-term resistance around $182, while fundamental strength supports longer-term upside potential if revenue momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
